You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of small near-infrared laser system capable of improving immune respo

    SBC: SEMINEX CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad and long-term objective of this project is to amplify the effectiveness of vaccines without the use of chemical or biological adjuvants. We will address this objective by demonstrating the feasibility for small laser- based devices to enhance responses to intradermal vaccination. A number of investigators have shown that a promising new way to make va ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. An innovative in situ cell reprogramming technology for cancer treatment

    SBC: QURGEN, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We invented an innovative protein induced Pluripotent Stem Cells (piPSCs) technology that generates piPSCs from normal fibroblast and cancer cells within 1-week with 90 4% conversion efficiency. Such high conversion efficiency enables us to pioneer an in situ cell reprogramming technology within the cancers of cancer-bearing animals. Instead of generating iPSCs ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Accurate Prostate Cancer Diagnosis for Active Surveillance Patients Using a Novel

    SBC: ProDevice Medical Supplies and Equipment LLC            Topic: NCI

    Project Abstract Active surveillance (AS) is becoming more accepted as a reasonable treatment option for men with low-risk prostate cancer (i.e. Gleason score 6, clinical stage T2a, PSA lt 10). Many AS protocols at major institutions call for a prostate saturation biopsy after initial diagnosis to confirm that the patient has no areas of higher-risk prostate cancer. For most patients who underwent ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic Utility of renalase and renalase peptides in cisplatin-mediated renal

    SBC: BESSOR PHARMA, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Cisplatin is a cornerstone therapy for a number of cancers including testicular, bladder, ovarian and lung. It is also used to treat cancers in children. In all cases there is a high incidence of acute kidney injury (AKI) that can also lead to later stage kidney damage. This risk limits its use. We have found in pilot studies that renalase, or peptide fragment ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. DNP Polarization Agents for Real-Time Metabolic Imaging and Clinical Diagnosis

    SBC: DYNUPOL, INC.            Topic: NCI

    Project Summary / Abstract Although standard MRI techniques provide valuable structural insight, a related technique known as magnetic resonance spectroscopy (MRS) adds powerful real-time metabolic information about the tissues under study. MRS provides early detection of disease, monitoring treatment efficacy, and, in the case of cancer, a dramatic reduction in unnecessary biopsies. However, bro ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Developing Inhibitors of the STARS/SRF Pathway for Treatment of Type 2 Diabetes

    SBC: Jenesis Biosciences LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Type 2 diabetes (T2D) has reached epidemic proportions in the United States, affecting an estimated 8.3% of the population. Unfortunately, the majority of individuals with diabetes continue to have suboptimal control ofglucose, therefore new and improved approaches to prevention and treatment are sorely needed. Dr. Mary Elizabeth Patti's laboratory at the ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel scFv-Antibody Fusion siRNA Carrier Protein for Macroglobulinemia Treatment

    SBC: SIRNAX, Inc.            Topic: NCI

    This goal of this project is to develop an innovative process for treating patients with Waldenstr m's macroglobulinemia by suppressing the production of IgM. Waldenstr m's macroglobulinemia is incurable and fatal. The manifestations of this disease that are due to high concentrations of monoclonal IgM are hyperviscosity with headache, fatigue, impaired cognition, confusion, and stroke, ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. F10: a novel therapeutic to treat refractory or relapsed AML

    SBC: SOUTHEAST TECHINVENTURES INC            Topic: NCI

    DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) affected ~14,600 new patients in 2013 in the US and caused over 10,000 deaths, primarily in older adults. The current chemotherapy regimen, a combination of cytarabine (AraC) and anthracyclines such as daunorubicin (DNR), has resulted in 5-year survival rates of only 30-40% (less than 10% in patients over 60 years old). The principa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government